Drug treatments for obesity: Where are we heading and how do we get there?

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 3, 2007, Pages 111-118

  Sonnenberg, Gabriele E ^a   Matfin, Glenn ^a   Reinhardt, Rickey R ^a  

^a NOVO NORDISK INC   (United States)

Author keywords

Anti obesity drugs; Bariatric surgery; Diabetes; Metabolic syndrome; Obesity

Indexed keywords

ANTIOBESITY AGENT; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BLOATING; BLOOD PRESSURE; CALORIC INTAKE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIARRHEA; DIET THERAPY; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSPEPSIA; ENERGY EXPENDITURE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART RATE; HOMEOSTASIS; HUMAN; INSOMNIA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LONG TERM CARE; METABOLIC SYNDROME X; MOOD DISORDER; NAUSEA; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; REVIEW; SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

EID: 34547669158     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070030301     Document Type: Review

References (35)

1. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Available at: http://www.cdc.gov/nchs/ about/major/nhanes/datalink.htm
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.
3. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of Overweight and Obesity in the United States, 1999-2004. JAMA 2006; 295:1549-55.
4. Peeters A, Barendregt JJ, Willekens F et al. Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis. Ann Intern Med 2003;138:24-32.
5. Mokdad A, Marks J, Stroup D, Gerberding J. Correction: Actual Causes of Death in the United States, 2000 JAMA 2005;293:293-4.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP, Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. World Health Organization. Report of a WHO consultation on obesity. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 1998. Available at: who.int/home/info.html
8. Yusuf S, Hawken S, Ôunpuu S, on behalf of the INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9.
9. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
10. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome - a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
11. Small CJ, Bloom SR. The therapeutic potential of gut hormone peptide YY336 in the treatment of obesity. Expert Opinion Invest Drugs 2005;14:647-53.
12. Small CJ, Parkinson JR, Bloom SR. Novel therapeutic targets for appetite regulation. Current Opinion Invest Drugs 2005;6:369-72.
13. Black, SC. Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drug 2004;5:389-94.
14. Ravinet Trillou C, Delgorge C, Menet C et al. Cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-8.
15. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.
16. Kissebah AH, Krakower GR, Sonnenberg GE, Hennes MMI. Clinical manifestations of the metabolic syndrome. In: Handbook of Obesity. Bray GA, Bouchard C, James WPT, editors. Marcel Dekker, Inc. New York;1997:601-36.
17. Brochu M, Tchernof A, Dionne IJ et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001; 86:1020-5.
18. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995;3:5211-S216.
19. Wadden TA, Anderson DA, Foster GD. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5-10% reduction in initial weight: some findings and some questions. Obes Res 1999; 7:170-8.
20. Singh RB, Rastogi SS, Verma R et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992;304: 1015-19.
21. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
22. Thorogood M, Hillsdon M, Summerbell C. Changing behaviour. Clinical Evidence 2002;6:31-49.
23. Bravata DM, Sanders L, Huang J et al. Efficacy and safety of low carbohydrate diets: a systematic review. JAMA 2003; 289:1837-50.
24. Freedman MR, King J, Kennedy E. Popular diets: A scientific review. Obes Res 2001;9:51-540.
25. Astrup A, Grunwald GK, Melanson EL et al. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord 2000; 24:1545-52.
26. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991; 115:956-61.
27. Buchwald, H. Consensus Conference Statement Bariatric surgery for morbid obesity: Health implications for patients, health professionals, and third-party payers. Obes Surg Relat Dis 2005;1:371-81.
28. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155-61.
29. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 2003;27:1437-46.
30. Padwal RS, Majundar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7.
31. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12:1197-211.
32. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151-85.
33. Food and Drug Administration (FDA): Guidance for Industry Developing Products for Weight Management, 14th February 2007. Available at: http://www.fda.gov/cder/guidance/7544dft.pdf. (Accessed 17th March 2007).
34. Committee for medicinal products for human use (CHMP): guideline on clinical investigation of medicinal products used in weight control available at: http://www.emea.europa.eu/pdfs/human/ewp/028196en.pdf. (Accessed 17th March 2007).
35. Sjöström L, Lindroos AK, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-9.